The Role of the Vascular Phase in Solid Tumor Growth: A Historical Review

Neoplasia

Volumn 1, Issue 4, 1999, Pages 293-302

  Ribatti, Domenico ^a   Vacca, Angelo ^a   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; History of medicine; Solid tumor

Indexed keywords

ANIMAL; ARTICLE; BIOLOGICAL MODEL; HISTORY; HUMAN; IMMUNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANIMALS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033205573     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900038     Document Type: Review

References (143)

1. Goldman E (1907). The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet ii, 1236-1240.
2. Clark ER, Hitschler WJ, Kirby-Smith HT, Rex RO, and Smith JH (1931). General observations on the ingrowth of new blood vessels into standardized chambers in the rabbit's ear, and the subsequent changes in the newly grown vessels over a period of months. Anat Rec 50, 129-167.
3. Clark ER, and Clark EI (1939). Microscopic observations on the growth of blood capillaries in the living mammals. Am J Anat 64, 251-301.
4. Ide AG, Baker NH, and Warren SL (1939). Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chambers. AJR 32, 891-899.
5. Algire GH, and Chalkley HW (1945). Vascular reactions of normal and malignant tissue in vivo. J Natl Cancer Inst 6, 73-85.
6. Merwin RM, and Algire GH (1956). The role of graft and host vessels in vascularization of grafts of normal and neoplastic tissues. J Natl Cancer Inst 17, 23-33.
7. Greenblatt M, and Shubik P (1968). Tumor angiogenesis: transfilter diffusion studied in the hamster by the transparent chamber technique. J Natl Cancer Inst 41, 111-124.
8. Ehrmann RL, and Knoth M (1968). Choriocarcinoma: transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. J Natl Cancer Inst 41, 1239-1241.
9. Folkman J, Merler E, Abernathy C, and Williams G (1971). Isolation of a tumor fraction responsible for angiogenesis. J Exp Med 133, 275-288.
10. Tuan D, Smith S, Folkman J, and Merler E (1973). Isolation of the nonhistone proteins of rat Walker 256 carcinoma. Their association with tumor angiogenesis. Biochemistry 12, 3159-3165.
11. McAuslan BR, and Hoffman H (1979). Endothelium stimulating factor from Walker carcinoma cells. Relation to tumor angiogenic factor. Exp Cell Res 119, 181-190.
12. Weiss JB, Brown RA, Kumar S, and Phillips P (1979). An angiogenic factor isolated from tumours: a potent low-molecular weight compound. Br J Cancer 40, 493-496.
13. Fenselau A, Kaiser D, and Wallis K (1981). Nucleoside requirements for the in vivo growth of bovine aortic endothelial cells. J Cell Physiol 108, 375-384.
14. Maciag T, Mehlman T, Friesel R, and Schreiber AM (1984). Heparin binds endothelial cell growth factor, the principal cell mitogen in bovine brain. Science 225, 932-935.
15. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, and Klagsbrun M (1984). Heparin-affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 223, 1296-1298.
16. Ferrara N, and Henzel WJ (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161, 851-855.
17. Plouet J, Schilling J, and Gospodarowicz D (1989). Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 8, 3801-3807.
18. Shing Y, Folkman J, Haudenschild C, Lund D, Crum R, and Klagsbrun M (1985). Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem 29, 275-287.
19. Bohlem P, Baird A, Esch F, Ling N, and Gospodarowicz D (1984). Isolation and partial molecular characterization of pituitary fibroblast growth factor. Proc Natl Acad Sci USA 81, 5364-5368.
20. Gospodarowicz D, Cheng J, Lui GM, Baird A, and Bohlen P (1984). Isolation of brain fibroblast growth factor by heparin-sepharose affinity chromatography: identity with pituitary fibroblast growth factor. Proc Natl Acad Sci USA 81, 6963-6967.
21. Esch F, Baird A, Ling N, Veno N, Hill F, Denoroy L, Klepper R, Gospodarowicz D, Bohlen P, and Guillemin R (1985). Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci USA 82, 6507-6511.
22. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, and Ferrara N (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
23. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, and Dvorak HF (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluids. Science 219, 983-985.
24. Kech PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, and Connolly DT (1989). Vascular permeability factor, an endothelial cell mitogen related to platelet derived growth factor. Science 246, 1309-1312.
25. Conn G, Bayne ML, Soderman DD, Kwok PW, and Sullivan KA (1990). Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 82, 2628-2632.
26. Gospodarowicz D, Abraham JA, and Schilling J (1989). Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculostellate cells. Proc Natl Acad Sci USA 86, 7311-7315.
27. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley B, Delfino JJ, Seigel NR, Leimgruber RM, and Feder J (1989). Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84, 1470-1478.
28. Levy AP, Tamargo R, Brem H, and Nathans D (1989). An endothelial cell growth factor from the mouse neuroblastoma cell line NB41. Growth Factors 2, 9-19.
29. Senger D, Brown L, Claffey K, and Dvorak A (1995). Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis 14, 385-394.
30. Pepper MS, Ferrara N, Orci L, and Montesano R (1992). Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189, 824-831.
31. Goto F, Goto K, Weindel K, and Folkman J (1993). Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on bovine capillary endothelial cells within collagen gels. Lab Invest 69, 508-571.
32. Asahara T, Bauters C, Zheng L, Takeshita S, Bunting S, Ferrara N, Symes JF, and Isner JM (1995). Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92, S365-S371.
33. Brem SS, Gullino PM, and Medina P (1977). Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 195, 880-882.
34. Brem SS, Jensen HM, and Gullino PM (1978). Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 41, 239-244.
35. Maiorana A, and Gullino PM (1978). Acquisition of angiogenic capacity and neoplastic transformation in the rat mammary gland. Cancer Res 38, 4409-4414.
36. Folkman J, and Hochberg M (1973). Self-regulation of growth in three-dimension. J Exp Med 138, 745-753.
37. Gimbrone MA Jr, Leapman S, Cotran RS, and Folkman J (1972). Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136, 261-276.
38. Folkman J, Lang DM, and Becker FF (1963). Growth and metastasis of tumor in organ culture. Cancer 16, 453-467.
39. Cavallo T, Sade R, Folkman J, and Cotran RS (1972). Tumor angiogenesis: rapid induction of endothelial mitosis demonstrated by autoradiography. J Cell Biol 54, 408-420.
40. Cavallo T, Sade R, Folkman J, and Cotran RS (1973). Ultrastructural autoradiographic studies of the early vasoproliferative response in tumor angiogenesis. Am J Pathol 70, 345-362.
41. Gimbrone MA Jr, Cotran RS, Leapman SB, and Folkman J (1974). Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 52, 413-427.
42. Folkman J, Watson K, Ingber D, and Hanahan D (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61.
43. Nicosia RF, Tchao R, and Leighton J (1986). Interactions between newly formed endothelial channels and carcinoma cells in plasma clot culture. Clin Exp Metastasis 4, 91-104.
44. Hanahan D (1985). Heritable formation of pancreatic beta-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogene. Nature 315, 115-122.
45. Kandel J, Bossy-Wetzel E, Radvanyl F, Klagsbrun M, Folkman J, and Hanahan D (1991). Neovascularization is associated with a switch to the export of bFGF. Cell 66, 1095-1104.
46. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, and Fuks Z (1990). Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9, 203-226.
47. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, and Nuseir N (1987). Macrophage-induced angiogenesis is mediated by tumor necrosis factor-α. Nature 329, 630-632.
48. Rastinejad F, Polverini PJ, and Bouck NP (1989). Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56, 345-355.
49. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, and Bouck NP (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87, 6624-6628.
50. Dameron KM, Volpert OV, Tainsky MA, and Bouck N (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584.
51. Bornstein P (1992). Thrombospondins: structure and regulation of expression. FASEB J 6, 3290-3293.
52. Hori A, Sasada D, Matsutani E, Naito K, Samura Y, Fijta T, and Kozay Y (1991). Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51, 6180-6184.
53. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N (1993). Inhibition of vascular endothelial growth factor-induced growth in vivo. Nature 362, 841-844.
54. Millauer B, Shawyer LK, Plate KH, Risau W, and Ullrich A (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.
55. Liotta LA, Kleinerman J, and Saidel GM (1974). Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34, 997-1004.
56. Dvorak HF, Brown LF, Detmar M, and Dvorak AM (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146, 1029-1039.
57. Butler TP, and Gullino PM (1975). Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 35, 512-516.
58. Zetter BR (1998). Angiogenesis and tumor metastasis. Ann Rev Med 49, 407-424.
59. Crum R, Szabo S, and Folkman J (1985). A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230, 1375-1378.
60. D'Amato RJ, Loughnan MS, Flynn E, and Folkman J (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91, 4082-4085.
61. Ingber DE, Fujita T, Kishimoto S, Sudo K, Kanamanu K, Brem H, and Folkman J (1990). Angioinhibins: synthetic analogues of fumagillin which inhibit angiogenesis and suppress tumor growth. Nature 348, 555-557.
62. Konno H, Tanaka T, Matsuda I, Kanai T, Maruo Y, Nishino N, Nakamura S, and Baba S (1995). Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 61, 268-271.
63. Mori S, Ueda T, Kuratsu S, Hosono N, Izawa K, and Uchida A (1995). Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 61, 148-152.
64. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, and Steegs PS (1994). Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54, 6504-6511.
65. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, and Folkman J (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
66. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, and Folkman J (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
67. Kolber DL, Knisely TL, and Maione TE (1995). Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 87, 304-309.
68. Holmgren L, O'Reilly, and Folkman J (1995). Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1, 149-153.
69. Brem S, Cotran R, and Folkman J (1972). Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48, 347-356.
70. Weidner N, Sample JP, Welch WR, and Folkman J (1991). Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. New Engl J Med 324, 1-8.
71. Gasparini G, and Harris A (1995). Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool: review. J Clin Oncol 13, 765-782.
72. Srivastava A, Laider P, Davies R, Horgan K, and Hughes L (1988). The prognostic significance of tumor vascularity in intermediate thickness (0.76-4 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol 133, 419-423.
73. Weidner N, Carroll PR, Flax J, Blumenfeld W, and Folkman J (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143, 1-9.
74. Brawer MK (1996). Quantitative microvessel density, a staging and prognostic marker for human prostatic carcinoma. Cancer 78, 345-349.
75. Yamazaki K, Abe S, Tekekawa H, Sukoh N, Watanabe N, Ogura S, Nakajima I, Isobe H, Inoue K, and Kawakami Y (1994). Tumor angiogenesis in human lung adenocarcinoma. Cancer 74, 2245-2250.
76. Angeletti CA, Lucchi M, Fontanini G, Mussi A, Chella A, Ribechini A, Vignati S, and Bevilacqua G (1996). Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2): impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer 78, 409-415.
77. Maeda K, Chung YS, Takasuka S, and Ogawa Y (1995). Tumor angiogenesis is a predictor of recurrence in gastric carcinoma. J Clin Oncol 13, 477-481.
78. Wiggins DL, Granai CO, Steinhoff MM, and Calabresi P (1995). Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol 56, 353-356.
79. Hollingsworth HC, Kohn EC, Steinberg SM, Rothengerg ML, and Merino MJ (1995). Tumor angiogenesis in advanced stage ovarian carcinoma Am J Pathol 147, 33-41.
80. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, Testolin A, and Bevilacqua P (1993). lntratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous-cell carcinoma. Int J Cancer 55, 739-744.
81. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, and Dammacco F (1994). Bone marrow angiogenesis and progression in multiple myeloma. Br J Hematol 87, 503-508.
82. Vacca A, Ribatti D, Presta M, Minischetti M, lurlaro M, Ria R, Albini A, Bussolino F, and Dammacco F (1999a). Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93, 3064-3073.
83. Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, Marzullo A, Herken R, Roncali L, and Dammacco F (1999). Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 79, 451-455.
84. Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, and Dammacco F (1996). Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Hematol 56, 45-53.
85. Ribatti D, Nico B, Vacca A, Marzullo A, Calvi N, Roncali L, and Dammacco F (1998). Do mast cells help angiogenesis in B-cell non-Hodgkin's lymphomas? Br J Cancer 77, 1900-1906.
86. Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, and Dammacco F (1999b). Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 79, 965-970.
87. Li VW, Folkerth R, Watanabe H, Yu C, Rupnick M, Barnes P, Scott RM, Black PM, Sallan SE, and Folkman J (1994). Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 344, 82-86.
88. Meyer G, Yu E, Siegal J, Petteway J, Blumenstein B, and Brawer M (1995). Serum basic fibroblast growth factor in men with and without prostate cancer. Cancer 76, 2304-2311.
89. Nguyen M, Watanabe H, Budson A, Richie J, Hayes D, and Folkman J (1994). Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86, 356-361.
90. Levy AP, Levy NS, Wegner S, and Goldberg MA (1995). Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270, 13333-13340.
91. Plate KH, Breier G, Widch HA, and Risau W (1992). Vascular endothelial growth factor is a potent tumor angiogenesis factor in human gliomas in vivo. Nature 359, 845-848.
92. Shweiki D, Itin A, Softer D, and Keshet E (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.
93. Hlatky L, Tsionou C, Hahnfeldt P, and Coleman CN (1994). Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor upregulation and protein expression. Cancer Res 54, 6083-6086.
94. Potgens AJ, Lubsen NH, van Alténa MC, Schoenmakers JG, Ruiter DJ, and De Waal RM (1995). Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 146, 197-209.
95. Claffey KP, Brown LF, Del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, and Dvorak HF (1996). Expression of vascular permeability factor/ vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56, 172-181.
96. Damert A, Machein M, Breier G, Fujita MQ, Hanahan D, Risau W, and Plate KH (1997). Upregulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res 57, 3860-3864.
97. Semenza GL (1996). Transcriptional regulation by hypoxia-inducible factor-1. Trends Cardiovasc Med 6, 151-157.
98. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, and Keshet E (1998). Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 394, 485-490.
99. Folkman J, and Berm H (1992). Angiogenesis and inflammation. In: Gallin J, Goldstein M, and Synderman R (Eds.), Inflammation: Basic Principles and Clinical Applications. Raven Press, New York, pp. 821-839.
100. Rollins BJ (1997). Chemokines. Blood 90, 909-928.
101. Watanabe K, Mc Cormick KL, Volker K, Ortaldo JR, Wiggington JR, Brunda MJ, Wiltrout RH, and Fogler WE (1997). Regulation of host-mediated anti-tumor mechanism of cytokines. Direct and indirect effects on leukocyte recruitment and angiogenesis. Am J Pathol 150, 1869-1880.
102. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, and Sorg C (1994). Macrophages and angiogenesis. J Leukocyte Biol 55, 410-422.
103. Leek RD, Lewis CE, and Harris AL (1997). The role of macrophages in tumour angiogenesis. In: Bicknell R, Lewis CE and Ferrara N (Eds.), Tumour Angiogenesis. Oxford University Press, Oxford, pp. 81-89.
104. Kessler DA, Langer RS, Pless NA, and Folkman J (1976). Mast cell and tumor angiogenesis. Int J Cancer 18, 703-709.
105. Starkey JR, Crowle PK, and Taubenberger S (1988). Mst cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 42, 48-52.
106. Norrby K, and Whooley D (1993). Role of mast cells in mitogenesis and angiogenesis in normal tissues and tumor tissues. Adv Biosci 89, 71-136.
107. Qu Z, Leibler JM, Powers MR, Galey T, Ahmadi P, Huang XN, Ansel JC, Butterfield JH, Planck SR, and Rosembaum JT (1995). Mast cell are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangiomas. Am J Pathol 147, 564-573.
108. Gruber BL, Marchese MJ, and Kew R (1995). Angiogenic factors stimulate mast cell migration. Blood 86, 2488-2493.
109. Grutzkau A, Kruger-Krasagakes S, Kogel H, Moller A, Lippert U, and Henz BM (1997). Detection of intracellular interleukin-8 in human mast cells: flow cytometry as a guide for immunoelectron microscopy. J Histochem Cytochem 45, 935-945.
110. Grutzkau A, Kruger-Krasagakes S, Baumesteir H, Schwarz C, Kogel H, Welker P, Lippert U, Henz BM, and Moller A (1998). Synthesis, storage and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF 206. Mol Biol Cell 9, 875-884.
111. Moller A, Henz BM, Grutzkau A, Lippert U, Aragane Y, Schwarz T, and Kruger-Krasagakes S (1998). Comparative cytokine gene expression: regulation and release by human mast cells. Immunology 93, 289-295.
112. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, and Klagsbrun M (1995). T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ cells. Proc Natl Acad Sci USA 91, 2890-2894.
113. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Nikdenjad K, Peoples GE, and Klagsbrun M (1995). Peripheral blood T lymphocytes and lymphocytes infiltrating human cancer express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55, 4140-4145.
114. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejwski C, Maisonpierre PC, and Yancopoulos GD (1996). Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87, 1161-1169.
115. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand S, Radziejwski C, Compton D, Mc Clain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, and Yancopoulos GD (1997). Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 277, 55-60.
116. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, and Breitman RL (1992). tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells, and their presumptive precursors. Oncogene 7, 1471-1480.
117. Partanen J, Armstrong E, Makela TP, Korhonen J, Sandberg M, Renkonen R, Knuutila S, Huebner K, and Alitalo K (1992). A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol 12, 1698-1707.
118. Sato TN, Quin Y, Kozak CA, and Audus KL (1993). Tie-1 and Tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci USA 90, 9355-9358.
119. Beck L Jr, and D'Amore PA (1997). Vascular development: cellular and molecular regulation. FASEB J 11, 365-373.
120. Sato TN, Tazawa Y, Deutsch U, Wolburg-Bucholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, and Quin Y (1995). Distinct roles of the receptor tyrosine kinase Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70-74.
121. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, and Yancopoulos GD (1996). Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171-1180.
122. Holash J, Maisonpierre PC, Compton D, Bolano P, Alexander CR, Zagzag D, Yancopoulos GD, and Wiegand SJ (1999). Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998.
123. Stratmann A, Risau W, and Plate KH (1998). Cell-type specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153, 1459-1466.
124. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, and Wands JR (1999). Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103, 341-345.
125. Orlidge A, and D'Amore PA (1987). Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 105, 1455-1462.
126. Antonelli-Orlidge A, Saunders KB, Smith SR, and D'Amore PA (1989). An activated form of transforming growth factor-β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86, 4544-4548.
127. Lindahl P, Johansson BR, Leveen P, and Betsholtz C (1997). Pericyte loss microaneurysm formation in PDGF-B deficient mice. Science 277, 242-245.
128. Hanahan D (1997). Signaling vascular morphogenesis and maintenance. Science 277, 48-50.
129. Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S, Tanaka N, and Yamamoto H (1999). Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 79, 501-509.
130. Rhodin JAG, and Fujita H (1989). Capillary growth in mesentery of normal young rats. Intravital video and electron microscope analyses. J Submicrosc Cytol Pathol 21, 1-34.
131. Leeven P, Perny M, Gebre-Medhin S, Swolin B, Larsson E, and Betsholtz C (1994). Mice deficient for PDGF-B show renal, cardiovascular and hematological abnormalities. Genes Dev 8, 1875-1887.
132. Wesseling P, Schlingemann RO, Reiveld FJ, Link M, Burger PC, and Ruiter DJ (1995). Early and extensive contribution of pericytes/ vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: an immunolight and immunoelectron microscopic study. J Neuropathol Exp Neurol 54, 304-310.
133. Williams AO, Ward JM, Jackson MA, and Flanders KC (1995). lmmunohistochemical localization of transforming growth factor-beta 1 in Kaposi's sarcoma. Hum Pathol 26, 469-473.
134. Folkman J (1971). Tumor angiogenesis: therapeutic implications. New Engl J Med 285, 1182-1186.
135. Eisenstein R, Sorgente R, Soble LW, Miller A, and Kuettner KE (1973). The resistance of certain tissues to invasion: penetrability of explanted tissues by vascularized mesenchyme. Am J Pathol 73, 765-774.
136. Castronovo V, and Belotti D. (1996). TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur J Cancer 32A, 2520-2527.
137. Schweigerer L, and Fotsis T (1991). Angiogenesis and angiogenesis inhibitors in paediatric diseases. Eur J Pediatr 151, 472-476.
138. Talbot DC, and Brown PD (1996). Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A, 2523-2533.
139. 3 for angiogenesis. Science 264, 569-571.
140. Friedlander M, Brooks PC, Shatter RW, Kincaid CM, Varner JA, and Cheresh DA (1995). Definitions of two angiogenic pathways by distinct integrins. Science 270, 1500-1502.
141. Gasparini G (1997). Anti-angiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications? Crit Rev Oncol Hematol 26, 142-162.
142. O'Reilly MS, Holmgren L, Chen C, and Folkman J (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2, 689-692.
143. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, and Angeletti CA (1992). Relation of neovascularization to metastasis of non-small cell-lung cancer. Lancet 340, 145-146.